Overview


According to FutureWise analysis the market for antithrombotic drugs in 2023 is US$ 45.09 billion, and is expected to reach US$ 84.33 billion by 2031 at a CAGR of 8.10%.

Antithrombotic drugs, also known as anticoagulants and antiplatelet agents, are medications used to prevent or treat blood clots. These drugs function by modulating the blood clotting process, essential in preventing excessive bleeding, but can also result in detrimental clots under specific medical circumstances. There are two main types of antithrombotic drugs: Antiplatelet Drugs inhibit the activation and aggregation of platelets, which are small blood cells crucial for clot formation. Antiplatelet drugs reduce the risk of arterial blood clots by preventing platelets from sticking together. Aspirin, Clopidogrel, and Ticagrelor are some common examples of this. Anticoagulants target the proteins involved in the coagulation cascade, a series of steps that lead to the formation of a blood clot. They delay the clotting process and are used to prevent or treat venous blood clots, including deep vein thrombosis and pulmonary embolism. Some anticoagulants are Warfarin, Heparin, Enoxaparin, Apixaban, Rivaroxaban, and Dabigatran.

Antithrombotic drugs are critical in preventing and managing conditions related to abnormal blood clotting, including atrial fibrillation, venous thromboembolism, stroke, heart attack, and specific cardiovascular procedures. 

FutureWise Market Research has published a report that provides an insightful analysis of Antithrombotic Drugs Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Antithrombotic Drugs Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Sanofi
  • Dr. Reddy’s Laboratories
  • Bayer AG
  • Boehringer Ingelheim Gmbh.
  • Genentech Inc.
  • Eli Lilly and Company
  • Johnson and Johnson Services Inc.
  • The Medicines Company
  • Pfizer Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Antithrombotic Drugs Market:

  • In March of 2022, CytoSorbents marked a significant milestone by enrolling the initial participant in the trial for DrugSorb-ATR, an anti-thrombotic removal system aimed at eliminating direct oral coagulants like apixaban and rivaroxaban during cardiothoracic surgery.
     
  • Furthermore, in February 2022, the United States Food and Drug Administration granted Fast Track designation to Bayer's oral Factor Xia inhibitor, Asundexian, currently in phase II trials. This designation acknowledges its potential as an anticoagulant for addressing arterial and venous thrombosis.

A steady increase in thrombotic disorders, including critical conditions like pulmonary embolism (PE) and deep vein thrombosis (DVT), is a significant driver for the market growth. As these disorders pose substantial health risks, there's a growing demand for effective antithrombotic therapies to prevent and treat these life-threatening events. The aging global population also plays a significant role in the market's expansion. Older individuals are more vulnerable to thrombotic events due to reduced mobility and increased comorbidities, necessitating advanced antithrombotic treatments to mitigate these risks.
However, there are challenges to this growth. Therapeutic intervention's potential side effects and safety concerns can influence market acceptance. Financial considerations also play a role, as the cost of antithrombotic therapies can be higher, which creates a financial burden and may hinder broader patient access, particularly in regions with strict healthcare budgets or insufficient insurance coverage. The complex path of drug development, marked by the need for research investments, extensive preclinical studies, and intricate clinical trials, can present hurdles. Regulatory complexities and the ever-present potential for setbacks in the development process contribute to challenges that must be adeptly navigated.
 

By Indication

  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Others

By Drug Class

  • Thrombolytic Drugs
  • Anti-Platelet Drugs
  • Anticoagulants
  • Others

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacy
  • Drug Store
  • Online Pharmacy
  • Retail Pharmacy

By Region

  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.
By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the growing cardiac and cancer diseases, rising healthcare expenditure, the increasing presence of major key players, and the rise in the adoption of newer technologies, further propelling the market growth.
 

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antithrombotic Drugs Market By Indication, By Drug Class, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Antithrombotic Drugs Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antithrombotic Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antithrombotic Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antithrombotic Drugs Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Pulmonary Embolism
        2. Deep Vein Thrombosis
        3. Atrial Fibrillation
        4. Others

  • 8.   Antithrombotic Drugs Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Thrombolytic Drugs
        2. Anti-Platelet Drugs
        3. Anticoagulants
        4. Others

  • 9.   Antithrombotic Drugs Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Oral
        2. Injectable

  • 10.   Antithrombotic Drugs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospital Pharmacy
        2. Drug Store
        3. Online Pharmacy
        4. Retail Pharmacy

  • 11.   North America Antithrombotic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Antithrombotic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Antithrombotic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Antithrombotic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •         1. Sanofi
                  1.1. Company Overview
                  1.2. Product Portfolio
                  1.3. SWOT Analysis
                  1.4. Financial Overview
                  1.5. Strategic Overview
              2. Dr. Reddy’s Laboratories
                  2.1. Company Overview
                  2.2. Product Portfolio
                  2.3. SWOT Analysis
                  2.4. Financial Overview
                  2.5. Strategic Overview
              3. Bayer AG
                  3.1. Company Overview
                  3.2. Product Portfolio
                  3.3. SWOT Analysis
                  3.4. Financial Overview
                  3.5. Strategic Overview
              4. Boehringer Ingelheim Gmbh.
                  4.1. Company Overview
                  4.2. Product Portfolio
                  4.3. SWOT Analysis
                  4.4. Financial Overview
                  4.5. Strategic Overview
              5. Genentech Inc.
                  5.1. Company Overview
                  5.2. Product Portfolio
                  5.3. SWOT Analysis
                  5.4. Financial Overview
                  5.5. Strategic Overview
              6. Eli Lilly and Company
                  6.1. Company Overview
                  6.2. Product Portfolio
                  6.3. SWOT Analysis
                  6.4. Financial Overview
                  6.5. Strategic Overview
              7. Johnson & Johnson Services Inc.
                  7.1. Company Overview
                  7.2. Product Portfolio
                  7.3. SWOT Analysis
                  7.4. Financial Overview
                  7.5. Strategic Overview
              8. The Medicines Company
                  8.1. Company Overview
                  8.2. Product Portfolio
                  8.3. SWOT Analysis
                  8.4. Financial Overview
                  8.5. Strategic Overview
              9. Pfizer Inc.
                  9.1. Company Overview
                  9.2. Product Portfolio
                  9.3. SWOT Analysis
                  9.4. Financial Overview
                  9.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11